694 A randomized phase II clinical trial of SBRT and pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c(BDCA-1)+/CD141(BDCA-3)+ myeloid dendritic cells in solid tumors - Bart Neyns; Bart Ilsen; Jens Tijtgat; Frederik Vandenbroucke; Inès Dufait; Sandra Tuyaerts; Ivan Van Riet; Xenia Geeraerts; Latoya Stevens; Manon Vounckx; Iris Dirven; Steven Raemaeckers; et al. (Journal for ImmunoTherapy of Cancer, 2023)